

10/5345789, 789

Rec'd I/PTO 13 MAY 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number
WO 2004/058939 A2

(51) International Patent Classification⁷:

C12N

(72) Inventor; and

(21) International Application Number:

PCT/US2003/035897

(75) Inventor/Applicant (for US only): TIEDGE, Henry [DE/US]; 108 East 96th Street #18D, New York, NY 10128 (US).

(22) International Filing Date:

12 November 2003 (12.11.2003)

(74) Agents: POKALSKY, Ann, R. et al.; Dilworth & Barrese, LLP, 333 Earle Ovington Boulevard, Uniondale, NY 11553 (US).

(25) Filing Language:

English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.





(26) Publication Language:

English

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: TRANSLATIONAL CONTROL BY SMALL, NON-TRANSLATABLE RNAs

 α -tubulin1.00 0.82 0.46 0.38 0.27
Signal Intensity (Relative Units)

(57) Abstract: The present invention provides isolated antisense molecules targeted to BC200 RNA. The subject antisense molecules are useful in treating various neurological disorders and carcinomas in a subject. Also provided are methods of treating a neurological disorder or cancer in a subject by administering a therapeutically effective amount of a subject antisense molecule. A method for treating epilepsy in a patient by administering an effective amount of BC200 RNA is also provided. Further, kits comprising a subject antisense molecule and a pharmaceutically acceptable carrier are provided by the present invention.

WO 2004/058939 A2



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*